Contera Pharma, a subsidiary of Bukwang Pharmaceutical, attracts investment from Medici Investment

3 million dollars invested by Medici Investment European Clinical phase 2 study of JM-010 to treat dyskinesia in Parkinson’s disease has been started Contera Pharma ApS (“Contera”), a subsidiary of Bukwang Pharmaceutical, has booked 3 billion KRW series A financing from Medici Investment. The proceeds from the financing will go to speed up the European […]

Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries

to be completed within 2 years Bukwang Pharmaceutical (“Bukwang”) announced today that the phase 2 clinical study of JM-010, a new potential treatment for dyskinesia in Parkinson’s disease, has recently been initiated. JM-010 is currently developed by Copenhagen-based Contera Pharma, a subsidiary of Bukwang. About 90% of patients who have been taking L-dopa for 10 […]

Bukwang Announces approval of Clinical Trial Application by European authority to initiate Phase 2 study of JM-010

Bukwang Pharmaceutical announces that the company’s application to conduct phase 2 clinical study for new CNS drug candidate ‘JM-010’ has recently been approved by French authority. The study is planned to include major European countries, including Germany, France, and Spain, with approvals from other countries are also expected to be completed within this month with […]

Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered patents on a therapeutic candidate for Levodopa-induced dyskinesia in Parkinson’s disease. – International application and registration of patents on therapeutic use and composition, formulations and metabolites for Levodopa-induced dyskinesia in Parkinson’s disease.

Bukwang said it registered patents on the use and composition of ‘JM-010’ with Korean Intellectual Property Office (Title : Combinations of serotonin receptor agonists for treatment of movement disorders). ‘JM-010’ is a treatment for ‘Levodopa-induced dyskinesia in Parkinson’s disease’ developed by Bukwang’s subsidiary named Contera Pharma ApS, which is a Danish bio venture specialized in […]

Bukwang Pharmaceutical Co., Ltd. LID treatment ‘JM-010’ is approved for Orphan Drug Designation

Bukwang recently announced that Ministry of Food and Drug Safety (MFDS) has granted JM-010 for the treatment of levodopa-induced dyskinesia (LID). JM-010 is currently being developed by a CNS specialized bioventure Contera Pharma, a subsidiary of Bukwang. LID is a movement disorder occurs inevitably in 60~70% of Parkinson’s disease patients who receive long-term levodopa treatment. […]

Press release, JM-010CS01, Phase IIa/cPoC study

Bukwang Pharma and its fully owned subsidiary Contera Pharma are pleased to announce that the investigational medical product, JM-010 has successfully been dosed to cohorts of patients with Parkinson’s disease suffering from moderate to severe levodopa-induced dyskinesia in a Phase IIa/Proof-of-Concept study. The primary study objectives concerning efficacy and safety were fulfilled. The aim is […]